Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

More documents

Recommendations

Info

206 Special Solidarity Fund KCE Reports 133 Name Active substance Indication CIP UCD Source Remodulin tréprostinil pulmonary hypertension Viagra/revatio pulmonary hypertension Ilomedine iloprost pulmonary hypertension CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités: sinds 10/2005 CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités: sinds 04/2006 CIP: Médicament NON Remboursable aux Assurés Sociaux (A) / Agrées aux collectivités: sinds 1992 UCD: Rétrocession: 100% (sinds 31/12/2005) - TAA: 01/04/2006 UCD: Rétrocession: 100% (sinds 09/2006) - Médicament Non facturable en sus de la TAA Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Elvorine cerebral folate deficiency Not found in the nomenclature Not found in the nomenclature No information found Calcort déflazacort Myozine alglucosidase alfa Pompe disease duchenne muscular dystrophy- syndrome néphrotique Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Sovrima idebenone Friedreic's ataxia Not found in the nomenclature Not found in the nomenclature No information found Ditropan for intravesical application implant cochléaire contralétéral (donc en fait bilatéral) implant crânien sur mesure électrodes corticales intégra oxybutynin chloride incontinency neurogenic bladder CIP: depending on the product; Homologation Assurés Sociaux (A) - 100% - sinds 10/01/2006 (reexamen in 2013) / Agrées aux collectivités: sinds 06/2006 Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) Sensori-neural hearing loss Not found in the nomenclature Not found in the nomenclature No information found "lack" of bones of the skull (after accident, operation, malformation,,,) mise au point en vue d'envisager une intervention au niveau de l'encéphale en cas d'épilepsie réfractaire in case of skin graft as a consequence of a fire, suite à des brûlres, diverse impairments (accidents…) Not found in the nomenclature Not found in the nomenclature No information found Not found in the nomenclature Not found in the nomenclature No information found Not found in the nomenclature Not found in the nomenclature No information found implant de l'oreille moyenne Sensori-neural hearing loss Not found in the nomenclature Not found in the nomenclature No information found pace maker diaphragmatique diafragmatic paralysis Not found in the nomenclature Not found in the nomenclature No information found contrathion CIP: Médicament NON Remboursable aux Assurés Sociaux (A) wel Homologation Collectivité C sinds 1995 Not found= not reimbursed under the statutory health insurance (l'Assurance Maladie obligatoire) Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires) cystadane homocystinuria CIP: Médicament NON Remboursable aux Assurés Sociaux (A) wel Homologation Collectivité C sinds 04/2008 UCD: Rétrocession: 65% (sinds 04/2008) - Médicament Non facturable en sus de la TAA Mrs. Isabelle Chenney + Nomenclature Assurance Maladie (Base des médicament et informations tarifaires)
KCE Reports 133 Special Solidarity Fund 207 9.17.3 Spain Name Activ sustance Indication a type of SCID (severe combined immunodeficiency syndrome) caused by the chronic deficiency of the adenosine deaminase (ADA) enzyme Reimbursement Adagen Pegademase bovine Vidaza Azacitidine myelodysplastic syndrome Hospital use Financed NHS without any co‐payment of the patient Kuvan sapropterin dihydrochloride phenylketonuria (PKU) ‐ tetrahydrobiopterin defiency Hospital use Financed NHS without any co‐payment of the patient auto immunology diseases ‐ neophrotic syndrome Diagnose by medical specialist Co‐payment of the patient 10% Cellcept Mycophenolate mofetil max.2,64€ Mabthera Rituximab Heamatologic oncology (leukemia ‐ lymphoma) brain tumors (glioblastoma) ‐ eye disorders‐cancer colon Hospital use Financed NHS without any co‐payment of the patient Avastin Bevacizumab métatasé 2ième intention‐tumeur de l'ovaire Hospital use Financed NHS without any co‐payment of the patient glucamylase & invertase enzyme deficiency sucrose isomaltase Bi‐myconase and/or sucraid (saccharase) Ointmenst, disinfectants, painkillers, tape, food supplements epidermolysis bullosa ‐ ichthyosis Implantable cardiac valves (aortic valves) degenerative valve disease (aged persons) In hospital's budget Implantable pulmonary valves congenital cardiac malformations (children) Patients who have no remaining auditory nerves (ex. Bilateral In hospital's budget Brainstem implant vestibular schwannomas tumors on both balance nerves) In hospital's budget Neuro stimulator of the stomach Severe gastro paresis Flolan époprosténol pulmonary hypertension Hospital use Financed NHS without any co‐payment of the patient Remodulin tréprostinil pulmonary hypertension Viagra/revatio pulmonary hypertension Hospital use Financed NHS without any co‐payment of the patient Ilomedine iloprost pulmonary hypertension Hospital use Financed NHS without any co‐payment of the patient Elvorine cerebral folate deficiency duchenne muscular dystrophy‐ syndrome néphrotique Other product ‐ on prescription for long time treatment co‐ Calcort déflazacort payment of 40% Myozine alglucosidase alfa Pompe disease Hospital use Financed NHS without any co‐payment of the patient Sovrima idebenone Friedreic's ataxia Ditropan for intravesical application oxybutynin chloride incontinency neurogenic bladder In hospital's budget implant cochléaire contralétéral (in hypoacusia fact bilatéral) In hospital's budget Cranial implant on messure shortage of cranial bone (after accident, operation or malformation) In hospital's budget corticale electrodes in case of refractive epilepsy awaiting surgery at encefale level In hospital's budget intégra skin substitute that regenerates dermis burn treatment implant in mid ear hypoacusia In hospital's budget diafragmatic pacemaker contrathion Diaphragmatic Paralysis In hospital's budget cystadane homocystinury Hospital use Financed NHS without any co‐payment of the patient
Page 1 and 2:
Optimalisatie van de werkingsproces
Page 3 and 4:
Optimalisatie van de werkingsproces
Page 5 and 6:
KCE reports 133A Bijzonder Solidari
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17:
Page 20 and 21:
2 Special Solidarity Fund KCE Repor
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
10 Special Solidarity Fund KCE Repo
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
Page 66 and 67:
Page 68 and 69:
Page 70 and 71:
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
100 Special Solidarity Fund KCE Rep
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175: 156 Special Solidarity Fund KCE Rep
Page 230 and 231: Wettelijk depot : D/2010/10.273/44
Page 232 and 233: 37. HTA Magnetische Resonantie Beel
Page 234: 108. Tiotropium in de behandeling v
show all

Optimalisatie van de werkingsprocessen van het Bijzonder ... - KCE

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?